Press Releases
Publications & Presentations
Events
Press Releases
May 31, 2023
PurIST® is an RNA expression-based test for pancreatic cancer molecular subtyping that can help inform and personalize cancer treatment Durham, N.C., May 31, 2023 – GeneCentric Therapeutics, a company making precision medicine…
May 16, 2023
The Alamance study will evaluate a novel FGFR Predictive Response Signature in development to personalize cancer treatment Durham, N.C., May 16, 2023 – GeneCentric Therapeutics, a company making precision medicine more precise…
April 12, 2023
Durham, NC, April 12, 2023 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced the appointment of Brian Kelly as Senior Vice President of Business Development. Mr.…
September 13, 2022
Durham, NC, September 13, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the poster presentation of further clinical validation data for PurISTSM, a novel RNA-expression…
August 23, 2022
A novel RNA-based IL-2 treatment response classifier was developed as part of the study in patients with renal cell carcinoma Durham, NC, August 23, 2022 – GeneCentric Therapeutics, a company making precision…
May 9, 2022
New HR-NMIBC molecular analyses to be presented at the 2022 AUA Annual Meeting Durham, NC, May 10, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today…
March 23, 2022
For two decades, scientists have been able to identify the molecular signature of specific cancers by isolating the RNA, responsible for dictating which proteins are produced and, by extension, how the cells…
March 16, 2022
New molecular analyses to be presented at the AACR Annual Meeting 2022 DURHAM, N.C.–(BUSINESS WIRE)– GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the upcoming oral…
December 20, 2021
The Piedmont Study, a Real-World Data Analysis in Patients Treated with Platinum Doublet Chemotherapy and/or Pembrolizumab, Identifies Predictive Biomarkers for Approved First-Line Treatments in NSCLC DURHAM, N.C.–(BUSINESS WIRE)– GeneCentric Therapeutics, a company…
December 20, 2021
GeneCentric CEO Michael Milburn discusses recent company accomplishments and the year ahead, as well as and current trends in biotech and pharma with WRAL TechWire. Read More
Publications & Presentations
LENS – Landscape of effective neoantigens software
April 5, 2022
Events
No results found.